Mepsevii Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited therapeutic options for mps vii, advancements in recombinant enzyme production, increasing recognition of rare genetic diseases, growth in orphan drug designations, improved diagnostic capabilities.

The growth in the forecast period can be attributed to expansion of rare disease treatment pipelines, rising investments in orphan drug development, increasing access to genetic testing, growing adoption of home-based infusion services, continued focus on improving patient quality of life. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on ultra-rare genetic disorders, growing demand for long-term disease management solutions, expansion of personalized rare disease treatments, enhanced emphasis on early diagnosis and intervention.

The increasing number of mucopolysaccharidosis (MPS) cases is expected to drive the growth of the Mepsevii market in the future. MPS disorders are a group of genetic diseases caused by the deficiency of specific enzymes that prevent the breakdown of glycosaminoglycans, leading to their accumulation in various organs and causing progressive damage. The rise in MPS cases can be attributed to improved diagnostic techniques, greater awareness among healthcare providers, and better access to genetic testing, which allow for earlier and more accurate detection of the disease. Mepsevii helps treat Mucopolysaccharidosis VII (MPS VII) by providing enzyme replacement therapy, replenishing the missing enzyme, beta-glucuronidase. For example, in March 2024, the Oregon Health Authority, a US-based public health agency, reported a birth prevalence of 1 in 73,290 for MPS II in Illinois in 2022, while Missouri recorded 1 in 96,297 in 2023, demonstrating the continued identification of new cases through newborn screening. Therefore, the increasing prevalence of MPS disorders is contributing to the growth of the Mepsevii market.

Major companies operating in the Mepsevii market are focusing on expanding global access initiatives, such as vestronidase alfa access-expansion programs. These are structured commercialization efforts aimed at introducing enzyme-replacement therapy into new countries through reimbursement activation, named-patient pathways, and specialized distribution channels to increase availability for individuals with MPS VII. For instance, in August 2024, Ultragenyx, a US-based biopharmaceutical company, introduced expanded international access efforts for Mepsevii, including new territory-specific reimbursement progress, broader geographic distribution enablement, and enhanced rare-disease commercial field teams to support therapy adoption across additional global markets.

In December 2024, Cerity Partners LLC, a US-based capital market company, acquired Ultragenyx Pharmaceutical Inc. for approximately $1.773 million. With this acquisition, Cerity Partners LLC gained 31,919 shares of Ultragenyx, aiming to strengthen its investment portfolio by expanding into the biotechnology sector, with a focus on companies specializing in rare diseases. Ultragenyx Pharmaceutical Inc. is a US-based biotech company that developed Mepsevii as part of its portfolio of treatments targeting rare genetic conditions.

Major companies operating in the mepsevii market are Ultragenyx Pharmaceutical Inc.

North America was the largest region in the mepsevii market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mepsevii market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mepsevii market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the mepsevii market by increasing costs of imported recombinant enzymes, bioprocessing consumables, sterile infusion systems, and specialized logistics required for rare disease therapies. North America and Europe are most affected due to reliance on global sourcing for enzyme replacement therapy components, while smaller markets face higher per-unit treatment costs. These tariffs contribute to elevated therapy prices and reimbursement challenges. However, they are also driving localization of biologics manufacturing, regional supply chain resilience, and strategic investments in rare disease production capabilities.

The mepsevii market research report is one of a series of new reports that provides mepsevii market statistics, including mepsevii industry global market size, regional shares, competitors with a mepsevii market share, detailed mepsevii market segments, market trends and opportunities, and any further data you may need to thrive in the mepsevii industry. This mepsevii market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mepsevii (vestronidase alfa) is an enzyme replacement therapy approved for the treatment of Mucopolysaccharidosis VII (MPS VII), a rare genetic disorder. It works by replacing the deficient enzyme beta-glucuronidase, aiding in the breakdown of harmful substances that accumulate in the body. This helps improve symptoms and enhance the quality of life for patients with MPS VII.

The main formulations of Mepsevii include intravenous infusion and pre-filled syringes. Intravenous infusion is a medical treatment where fluids, medications, or nutrients are delivered directly into the bloodstream through a vein. This method is commonly used for administering Mepsevii to patients, ensuring that the drug reaches the bloodstream efficiently for optimal therapeutic effects. Mepsevii is primarily used for treating Mucopolysaccharidosis VII (MPS VII, also known as Sly syndrome) and is distributed through hospitals, specialty clinics, home healthcare services, and pharmacies. It is utilized by end users, including pediatric and adult patients.

The mepsevii market consists of sales of mepsevii (vestronidase alfa-vjbk). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.